Prevention of transfusion-transmitted cytomegalovirus infection using leukoreduced blood components in patients receiving seronegative umbilical cord blood transplantation.

Tomonari ShigemuraRyu YanagisawaKazutoshi KomoriDaisuke MoritaTakashi KurataMiyuki TanakaKazuo SakashitaYozo Nakazawa

Published in: Transfusion (2019)

Using prestorage leukoreduction, no cases of CMV infection were detected in seronegative CBT patients. Our findings showed the safety of leukoreduction in preventing TT-CMV in this patient group.

Keyphrases

umbilical cord
mesenchymal stem cells
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
peritoneal dialysis
case report
cardiac surgery
patient reported outcomes
cell therapy